Ambalal Sarabhai Sets November 5 Board Results Meeting

Ambalal Sarabhai Enterprises Ltd will consider unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026, at a board meeting on November 5, 2026, following an 8% year-on-year rise in Q1 FY27 consolidated revenue to ₹43.56 crore.

What will Ambalal Sarabhai Enterprises consider on November 5?

Ambalal Sarabhai Enterprises Ltd has informed BSE that its board of directors is scheduled to meet on November 5, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The board will also consider the limited review report to be issued by the auditors on those interim financial statements.

The announcement was made on October 28, 2026. The September-quarter release will give investors the company's first reported view of performance for the first half of FY27. The disclosure does not provide financial estimates, business guidance, or any proposed corporate action.

The company had previously followed a similar reporting process for its June 2026 quarter. Its board approved unaudited standalone and consolidated Q1 FY27 results on August 12, 2026, along with the auditors' limited review report. Sorab S. Engineer & Co. issued an unqualified review report on the interim financial information, according to the available disclosure.

What did Ambalal Sarabhai Enterprises report in Q1 FY27?

Ambalal Sarabhai Enterprises reported consolidated revenue of ₹43.56 crore for the quarter ended June 30, 2026, up 8% from the corresponding quarter a year earlier. Consolidated net profit, however, declined 52% year-on-year to ₹3.98 crore from ₹8.22 crore in Q1 FY26.

The contrast between revenue growth and lower profit makes the September-quarter release important for assessing whether the June-quarter profit movement was isolated or part of a broader pattern. The currently available data does not specify the reasons for the year-on-year decline in Q1 net profit, so no conclusion on its drivers can be drawn from the announcement.

Historical quarterly revenue data shows that the company reported ₹44 crore of revenue for the June 2026 quarter, compared with ₹40 crore in June 2025, on the figures presented in the quarterly-results table. These rounded figures are directionally consistent with the separately reported 8% year-on-year revenue increase.

Why is the September-quarter filing important for investors?

The September-quarter results will cover both the three months ended September 30 and the first six months of FY27. This gives investors a broader basis to compare revenue and profitability with the June-quarter outcome and the corresponding prior-year period.

Ambalal Sarabhai Enterprises is classified under pharmaceuticals in the provided market data and is listed on BSE under code 500009. As a listed company, its periodic financial disclosures provide the formal basis for investors to review operational and financial performance. The forthcoming filing is an approval intimation, not a statement of results, and the actual September-quarter numbers had not been disclosed in the material provided.

The company also closed its trading window for dealing in its securities from October 1, 2026. The restriction will remain in force until 48 hours after the declaration of financial results for the quarter ended September 30, 2026. Such closures are intended to restrict trading by designated persons during the period surrounding unpublished price-sensitive information.

How does the announcement affect shareholders and market participants?

For shareholders, the immediate relevance is the date of the next official financial disclosure. The board's decision on November 5 will determine when the approved September-quarter and half-year figures, together with the limited review report, become available to the market.

The Q1 FY27 results provide the most recent disclosed financial reference point. Revenue grew to ₹43.56 crore, while consolidated net profit fell to ₹3.98 crore. Investors will be able to compare the September-quarter performance against these figures once the company releases the results, rather than relying on the board-meeting intimation alone.

The announcement does not state any change in the company's operations, product portfolio, capital allocation, dividend policy, or outlook. It also contains no information about a share-price movement. Therefore, the identifiable market implication is the scheduled release of reviewed interim financial information, not a confirmed change in business conditions.

What financial trend is visible from the available data?

The available quarterly revenue series shows variation across recent periods. Reported revenue was ₹40 crore in June 2025, ₹44 crore in September 2025, ₹52 crore in December 2025, ₹65 crore in March 2026, and ₹44 crore in June 2026. These figures show that quarterly revenue has moved materially from period to period.

For the year ended March 2026, the provided financial table reports total operating profit of ₹16.28 crore and net income available to common stockholders of ₹17.80 crore, both expressed after converting the stated INR million figures into crore. The same table reports gross profit of ₹74.29 crore. These annual measures offer context, but they are not a substitute for the unaudited Q2 FY27 and half-year results pending before the board.

Conclusion

Ambalal Sarabhai Enterprises has scheduled its November 5 board meeting to approve unaudited standalone and consolidated results for Q2 FY27 and the first half of FY27. The event follows a June quarter in which consolidated revenue increased 8% year-on-year to ₹43.56 crore while net profit declined 52% to ₹3.98 crore.

The next item to watch is the board-approved September-quarter filing and the accompanying limited review report. Those disclosures will provide the reported revenue, profit and half-year figures that are not included in the October 28 meeting intimation.